ghk-cu peptide risks side effects Therapy: Anti-Aging & Skin Rejuvenation | Desert Mobile Medical GHK-Cu Peptide | The benefits,

M., Heymsfield, S

As noted, the present knowledge is limited, and these are considerations, not strong recommendations

In animal models, intranasal administration of GHK-Cu improved cognitive functions, reduced amyloid plaques, and decreased inflammation in the brain, suggesting its potential as a therapeutic agent for Alzheimers disease and age-related cognitive decline 10

Recurrent gout attacks that arent treated may involve more joints, last longer, and become increasingly severe over time

The closest human evidence in its drug class is Athira Pharma's fosgonimeton (ATH-1017), a structurally distinct molecule in the same HGF/c-Met program whose Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint in September 2024 (GST 0.08, P=.70)

It is not FDA-approved for human use in any indication